Turn Therapeutics Announces Positive In-Vivo Data for Non-Melanoma Skin Cancer Candidate

Turn Therapeutics, a biotechnology company developing innovative products for infectious disease, advanced wound care, and dermatology, today announced positive in-vivo data for its therapeutic candidate (GX-03) as a non-invasive treatment for Basal Cell Carcinoma (BCC). Basal Cell Carcinoma is a highly prevalent, non-melanoma skin cancer with limited non-invasive treatment options.